Hepatitis/MASH

Glecaprevir/pibrentasvir found to be effective in clinical trials treating patients with hepatitis C virus also being treated for opioid substitution therapy.

Top news of the day from across the health care landscape.

A new review of clinical trial data show the combination therapy elbasvir/grazoprevir (EBR/GR) has high rates of efficacy for patients with genotypes 1a, 1b, and 4 chronic hepatitis C (HCV) infection.

In light of new evidence supporting the efficacy of hepatitis C virus (HCV) treatments in individuals who use or inject drugs, researchers are urging the removal of restrictions that prevent recent drug users from accessing lifesaving HCV therapies.

Based on evidence from a systematic review, researchers are calling for increased access to lifesaving hepatitis C treatments for injection drug users.

Top news of the week from Specialty Pharmacy Times.

Officials with Gilead Sciences, Inc. plan to launch authorized generic versions of Epclusa and Harvoni.

Study establishes real-world efficacy, tolerability, and safety profile of sofosbuvir-based regimens in patients with chronic hepatitis C who have compensated liver cirrhosis.

Top news of the day from across the health care landscape.

Study shows that it’s cost-effective to use the livers of HCV-positive patients even with the cost of direct-acting antiviral drugs to cure the virus.

Researchers have identified a potential point of intervention that could prevent the progression of liver damage to cancer.

Study identifies receptor as potential target for reversing liver damage and preventing progression to cancer.

Presenters at the International Pharmaceutical Federation (FIP) World Congress in Glasgow, Scotland identified the current landscape of Hepatitis C, how pharmacists can position themselves to aid in point of care testing, and ways to better educate patients and providers.

In its multiple-ascending dose trial, ARO-HBV demonstrated reductions in circulating hepatitis B virus surface antigen.

Officials with the FDA have approved Grifols’ new formulation of immune globulin (GamaSTAN) for hepatitis A virus and measles post-exposure prophylaxis.

The new formulation is the only immune globulin available in the United States that is approved for post-exposure protection against hepatitis A and measles.

If proven effective, GLS-6150 could be the first vaccine to protect against hepatitis C virus infection.

Study shows the safety and efficacy of treatment with sofosbuvir and velpatasvir in adults with recurrent chronic genotypes 1-4 HCV infection after liver transplant.

Genetically humanized mice may help researchers develop treatments for hepatitis D virus.

Top news of the week from Specialty Pharmacy Times.

Testing individuals not considered high-risk for hepatitis C virus addresses increase in new infections associated with opioid epidemic.

Lenvatinib (Lenvima) has been granted approval by the FDA as a first-line treatment for patients with unresectable hepatocellular carcinoma.

Researchers have developed a novel peptide drug that has the potential to reduce tumor growth and slow down the spread of cancer cells.

Organ transplant recipients who received infected kidneys were cured of hepatitis C after taking antiviral therapy following the procedure.

Study offers insight into the evolution of global dissemination of hepatitis B virus genotypes D and A.

The FDA has approved updates to the labeling for hepatitis C virus (HCV) drug glecaprevir and pibrentasvir (Mavyret) to include new data from 2 clinical studies.

The revised labeling for glecaprevir and pibrentasvir (Mavyret) includes data from clinical trials on the safety and efficacy of the treatment for HIV-1 coinfected patients and liver and kidney transplant recipients.

Interaction between hepatitis C virus and high alcohol consumption significantly limits patient survival.

Silvestrol inhibited the replication of pathogens in both cell cultures and in a mouse model.